Summary
PHMBIO+ is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €20,460 and a net result of €59,137. Equity is growing by about 7.4% per year across the filed financial years. Its solvency ranks better than 9% of 599 sector peers (NACE 66, financial year 2025). The company has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Connections & network
2 connected companiesThe connected companies are in the list below.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
GlaxoSmithKline Biologicals
Shared director
→
NOVADIP BIOSCIENCES
Shared director
→
Board mandates elsewhere
1 board mandateBoard mandates of this companythis company sits on their board1
1 location